Alvin has served as CEO of Enzyvant since November 2016. Prior to joining Enzyvant, Alvin was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Prior to joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Alvin has an MD from the University of Alabama, an MBA from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.
Chief Commercial Officer
Morgan has more than 25 years of broad commercial leadership experience in the biopharmaceutical industry. Prior to Enzyvant, he served as the Head of U.S. Commercial for Spark Therapeutics and was responsible for the development of commercial strategy and implementation in the U.S. for Spark’s investigational gene therapy programs. Starting in 2007, Morgan spent seven years at Sanofi-Genzyme and held multiple commercial leadership roles in several of the legacy Genzyme franchises, including the Fabry disease business. Morgan started his career at Allergan and Biogen and holds a BS in Business Management from the University of Massachusetts Lowell.
Judy Chuk, PhD
VP, Strategy & Operations
Judy is responsible for ensuring operational resources for advancement of Enzyvant’s portfolio and strategic development of the business. Judy is a bench scientist by training and brings over 10 years of strategic planning, business operations, and portfolio management experience across multiple therapeutic areas in the biopharma industry. Her experience spans across many functional areas including all phases of drug discovery, development, and commercialization. Most recently, she served as COO and Head of Strategy and Operations for Pfizer’s Rare Disease Research Unit in Cambridge, MA. Judy holds a PhD from Harvard University and a BA from Rutgers University.
Alex Solyom, MD
Senior Medical Director
Alex is a pediatrician by training, with years of clinical experience in pediatric rheumatology, immunology, and rare diseases including lysosomal storage diseases in particular. He has longstanding relationships with international physician colleagues and patient organizations in these fields. Alex most recently served as the global medical lead for Plexcera Therapeutics, helping build the Farber disease program as well as guiding a second program aimed at treatment of bone and joint disease in mucopolysaccharidosis through a Phase I/II trial.
Dustin Tetzl, MD
Dustin has been with Enzyvant since its inception in June 2016 and manages medical affairs and partnerships with physicians and scientific collaborators. Prior to Enzyvant, Dustin worked on the business development team at Roivant Sciences, Inc., sourcing and evaluating new opportunities in the rare disease space. Dustin completed his medical education at Columbia University College of Physicians and Surgeons, and has many years of experience as a consultant and entrepreneur in the medical education industry.
Michele Rhee, MBA, MPH
Head, Patient Affairs
Michele joined Enzyvant as the Head of Patient Affairs, following patient advocacy leadership roles at the National Brain Tumor Society, bluebird bio, and Takeda Oncology. As a member of the rare disease patient community for over a decade, Michele has dedicated her career to getting treatments to the patients who need them. Michele is a founding board member of Costs of Care and volunteers as a SAMbassador for SAMFund. She received her MBA from the Yale School of Management and her MPH from the Yale School of Public Health.